Pharmaceutical - Asia-Pacific

Filter

Current filters:

Asia-Pacific

Popular Filters

151 to 175 of 716 results

Novo Nordisk’s NovoEight passes first stage of Japanese approval

Novo Nordisk’s NovoEight passes first stage of Japanese approval

18-11-2013

Danish insulin giant Novo Nordisk’s recombinant factor VIII product NovoEight (turoctocog alfa) has…

Asia-PacificHematologyNovo NordiskNovoEightPharmaceuticalRare diseasesRegulation

Merck KGaA to invest 80 million euros in China pharma production

Merck KGaA to invest 80 million euros in China pharma production

15-11-2013

Germany’s Merck KGaA said this morning that it plans to invest 80 million euros ($106.8 million) in…

Asia-PacificFinancialMerck KGaAMerck SeronoPharmaceuticalProduction

UK’s Helperby in deal with Cadila on ARB research and commercialization

14-11-2013

Privately-held Indian drugmaker Cadila Pharmaceuticals and UK based antibiotics discovery company, Helperby…

Antibiotics and Infectious diseasesAsia-PacificCadila PharmaceuticalsHelperby TherapeuticsMarkets & MarketingPharmaceuticalResearch

Japan market entry challenges – by P Reed Maurer

Japan market entry challenges – by P Reed Maurer

14-11-2013

Not long ago, the last word in the title would have been obstacles rather than challenges, says P Reed…

Asia-PacificManagementMarkets & MarketingPharmaceutical

Japan NHI price listing for Chugai’s Kadcyla delayed

14-11-2013

Japanese drugmaker Chugai Pharmaceutical, which is majority owned by Swiss major Roche, says that the…

Asia-PacificChugai PharmaceuticalKadcylaOncologyPharmaceuticalPricingResearchRoche

Establishing a common regulatory framework for Australia and New Zealand

13-11-2013

As part of transitioning to an Australia New Zealand Therapeutic Products Agency, Australia’s Therapeutic…

Asia-PacificHealthcareNew ZealandPharmaceuticalRegulation

Incidence of post-herpetic neuralgia set for steady increase by 2022

11-11-2013

Due to the growth of the elderly population worldwide, the number of post-herpetic neuralgia (PHN) incident…

Asia-PacificEuropeMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Eisai enters agreement to develop treatments for neglected tropical diseases

Eisai enters agreement to develop treatments for neglected tropical diseases

11-11-2013

Eisai (TYO: 4523) has entered into a global agreement with the Broad Institute to jointly discover and…

Asia-PacificEisaiNorth AmericaPharmaceuticalResearchTropical diseases

New Zealand govt “tinkers around R&D tax deductibility,” says Labour

09-11-2013

New Zealand’s National Party Government’s call for feedback to resolve problems around the tax deductibility…

Asia-PacificFinancialNew ZealandPharmaceuticalPoliticsResearch

Eisai expands marketing and supply agreement for Belviq worldwide

Eisai expands marketing and supply agreement for Belviq worldwide

08-11-2013

Japanese drug major Eisai (TYO: 4523) has expanded the marketing and supply agreement between its US…

Asia-PacificBelviqEisaiGastro-intestinalsLicensingPharmaceutical

Trajenta studies prove efficacy in broad range of diabetes patients

Trajenta studies prove efficacy in broad range of diabetes patients

07-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released new data that reinforces the efficacy and…

Asia-PacificBoehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalResearchTrajentaUSA

Home Offices still don’t get Japan - by P Reed Maurer

Home Offices still don’t get Japan - by P Reed Maurer

07-11-2013

Many, fortunately not all, senior managers of foreign pharma companies in Japan constantly struggle with…

Asia-PacificManagementPharmaceutical

Cardiovascular risk a concern when prescribing diabetes treatments, survey finds

06-11-2013

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) revealed that 79% of nearly 800 physicians in four Asian…

Asia-PacificBoehringer IngelheimDiabetesEli LillyHealthcarePharmaceuticalResearch

Emerging markets to see fastest growth, as pharma industry faces challenges

05-11-2013

Globally, the scientific foundation on which the pharma industry rests has improved vastly over the years.…

Asia-PacificMarkets & MarketingPharmaceuticalRegulationSouth America

Sagent Pharma debuts Carboplatin Injection

Sagent Pharma debuts Carboplatin Injection

04-11-2013

US specialty drugmaker Sagent Pharmaceuticals has announced the launch of Carboplatin Injection, an antineoplastic…

Asia-PacificCarboplatinMarkets & MarketingNorth AmericaOncologyPharmaceuticalProductionSagent Pharmaceuticals

Bristol-Myers files for Japanese approval of first all-oral, interferon/ribavirin-free hep C treatment

Bristol-Myers files for Japanese approval of first all-oral, interferon/ribavirin-free hep C treatment

03-11-2013

US drug major Bristol-Myers Squibb has filed a New Drug Application with Japan’s Pharmaceutical and…

Anti-viralsAsia-PacificasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalRegulation

Eisai seeks expanded Japanese indication for Aricept

Eisai seeks expanded Japanese indication for Aricept

01-11-2013

Japanese drug major Eisai says it has filed an application for its already marketed anti-Alzheimer's…

AriceptAsia-PacificEisaiNeurologicalPharmaceuticalRegulation

Daiichi Sankyo sales up while Ranbaxy sales decline

Daiichi Sankyo sales up while Ranbaxy sales decline

01-11-2013

Daiichi Sankyo has released results for the fiscal period April 1 to September 30, showing net sales…

Asia-PacificDaiichi SankyoFinancialPharmaceuticalRanbaxy Laboratories

DSM celebrates opening of new biopharma cGMP facility in Australia

30-10-2013

DSM Pharmaceutical Products, the custom manufacturing and technology business of Netherlands-based Royal…

Asia-PacificDSM BiologicsDSM PharmaceuticalsPharmaceuticalProduction

Australia’s PBS lists new medicines and increases cost threshold to A$20 million

Australia’s PBS lists new medicines and increases cost threshold to A$20 million

30-10-2013

The Australian Federal Minister for Health, Peter Dutton, has announced that the cost of 50 new and amended…

Asia-PacificdabrafenibHealthcarePharmaceuticalPoliticsSutent

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Japan’s MoF seen as another opponent to premium system

Japan’s MoF seen as another opponent to premium system

29-10-2013

The Budget Bureau of Japan’s Ministry of Finance, in a meeting of the Fiscal System Council last week,…

Asia-PacificGenericsPharmaceuticalPricing

Roche and Chugai’s SC RoActemra improves RA long term

Roche and Chugai’s SC RoActemra improves RA long term

28-10-2013

Roche and its majority-owned Japanese subsidiary Chugai Pharmaceutical have announced that their RoActemra…

Anti-Arthritics/RheumaticsAsia-PacificChugai PharmaceuticalPharmaceuticalResearchRoActemraRoche

151 to 175 of 716 results

Back to top